Salmonella entericaTyphimurium engineered for nontoxic systemic colonization of autochthonous tumors / Lance B. Augustin, Liming Milbauer, Sara E. Hastings, Arnold S. Leonard, Daniel A. Saltzman, Janet L. Schottel
Abstract Much of the bacterial anticancer therapy being developed relies on the ability of bacteria to specifically colonise tumours. Initial attempts to translate promising Salmonella enterica Typhimurium ( S . Typhimurium) preclinical results to the clinical setting failed, primarily due to lack of tumour colonisation and the significant toxicities from systemically administered Gram-negative bacteria. To address the difference in results between preclinical experiments performed in mice with transplant tumours and clinical trials in human volunteers with autochthonous tumours, a genetically engineered mouse model of breast cancer (BALB-neuT) was utilised to develop a strain of virulence-attenuated S . Typhimurium capable of robust colonisation of autochthonous tumours. Several genes that code for bacterial surface molecules, responsible for signalling a toxic immune response against the bacteria, were mutated. The resulting S. Typhimurium strain, BCT2, allowed non-toxic intravenous administration of 3 × 10 6 colony forming units of bacteria in tumour-burdened mice when combined with a vascular disruption agent to induce intratumoral necrotic space and facilitate bacterial colonisation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Journal of drug targeting - 29(2021), 3, Seite 294-299 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Augustin, Lance B. [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
Autochthonous tumour colonisation |
|---|
| Umfang: |
1 Online-Ressource (6 p) |
|---|
| doi: |
10.1080/1061186X.2020.1818759 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011112972 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011112972 | ||
| 003 | DE-627 | ||
| 005 | 20230713210743.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230609s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/1061186X.2020.1818759 |2 doi | |
| 035 | |a (DE-627)KFL011112972 | ||
| 035 | |a (KFL)prod_LgpH_10.1080/1061186X.2020.1818759 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Augustin, Lance B. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Salmonella entericaTyphimurium engineered for nontoxic systemic colonization of autochthonous tumors |c Lance B. Augustin, Liming Milbauer, Sara E. Hastings, Arnold S. Leonard, Daniel A. Saltzman, Janet L. Schottel |
| 264 | 1 | |c 2021 | |
| 300 | |a 1 Online-Ressource (6 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Much of the bacterial anticancer therapy being developed relies on the ability of bacteria to specifically colonise tumours. Initial attempts to translate promising Salmonella enterica Typhimurium ( S . Typhimurium) preclinical results to the clinical setting failed, primarily due to lack of tumour colonisation and the significant toxicities from systemically administered Gram-negative bacteria. To address the difference in results between preclinical experiments performed in mice with transplant tumours and clinical trials in human volunteers with autochthonous tumours, a genetically engineered mouse model of breast cancer (BALB-neuT) was utilised to develop a strain of virulence-attenuated S . Typhimurium capable of robust colonisation of autochthonous tumours. Several genes that code for bacterial surface molecules, responsible for signalling a toxic immune response against the bacteria, were mutated. The resulting S. Typhimurium strain, BCT2, allowed non-toxic intravenous administration of 3 × 10 6 colony forming units of bacteria in tumour-burdened mice when combined with a vascular disruption agent to induce intratumoral necrotic space and facilitate bacterial colonisation | ||
| 653 | |a Bacterial cancer therapy | ||
| 653 | |a vascular disruption | ||
| 653 | |a autochthonous tumour colonisation | ||
| 653 | |a BALB-neuT | ||
| 653 | |a virulence-attenuatedSalmonellaTyphimurium | ||
| 700 | 1 | |a Milbauer, Liming |e verfasserin |4 aut | |
| 700 | 1 | |a Hastings, Sara E. |e verfasserin |4 aut | |
| 700 | 1 | |a Leonard, Arnold S. |e verfasserin |4 aut | |
| 700 | 1 | |a Saltzman, Daniel A. |e verfasserin |4 aut | |
| 700 | 1 | |a Schottel, Janet L. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of drug targeting |d Abingdon : Taylor & Francis Group, 1993 |g 29(2021), 3, Seite 294-299 |h Online-Ressource |w (DE-627)KFL000006076 |w (DE-600)2041932-6 |w (DE-576)273880632 |x 1029-2330 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2021 |g number:3 |g pages:294-299 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/tandf-ejournals-pharmazie/doi.org/10.1080/1061186X.2020.1818759 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-TFE | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_LgpH_02 | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2021 |e 3 |h 294-299 | ||